search
Back to results

Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection

Primary Purpose

Bloodstream Infection

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Seraph 100,The Microbind Affinity Blood Filter
Sponsored by
ExThera Medical Europe BV
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bloodstream Infection

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Patients with sepsis and suspected bloodstream infection
  2. Be ≥ 18 years old and ≤ 90 years old
  3. Adults receiving IV antibiotic therapy
  4. Increase of at least two points of the Sequential Organ Failure Assessment (SOFA) score
  5. Subjects that presents Procalcitonin (PCT) levels > 0,5 ng/mL

Exclusion Criteria:

  1. Subject is currently participating in another clinical investigation
  2. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
  3. Presence of comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
  4. The first dose of the current antibiotic therapy was > 24 h before screening
  5. Have Child-Pugh Class C cirrhosis
  6. Have platelet count < 30.000/uL
  7. Contraindications for heparin sodium for injection
  8. Subjects demonstrating any contraindication for this treatment as described in the IFU

Sites / Locations

  • Medical University of Innsbruck
  • Middelheim HospitalRecruiting
  • Hôpital Erasme
  • CHU Bocage Central
  • Hospices Civils de LyonRecruiting
  • Nouvel Hopital Civil
  • Klinikum Aschaffenburg-Alzenau
  • Vivantes Klinikum Neukölln
  • Städtisches Klinikum Braunschweig GmbHRecruiting
  • Universität Witten-HerdeckeRecruiting
  • Universitätsklinikum Essen (AöR)Recruiting
  • University Hospital FrankfurtRecruiting
  • Universitätsmedizin Greifswald
  • Asklepios Hospital St. Georg
  • Medizinische Hochschule Hannover
  • Universität RostockRecruiting
  • Azienda Usl Toscana CentroRecruiting
  • University Hospital, Pisa
  • A.Gemelli University Hospital
  • Ziekenhuis Gelderse Vallei
  • Medisch Spectrum TwenteRecruiting
  • Jagiellonia UniversityRecruiting
  • Hospital Universitari Vall d'Hebron
  • Hospital Clinico San Carlos
  • Royal Surrey NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

No Intervention

Arm Label

Treatment

Control

Arm Description

Treatment with Seraph Filter

Outcomes

Primary Outcome Measures

Reduction of pathogens load
Reduction of pathogens load from the bloodstream during treatment

Secondary Outcome Measures

All-cause mortality
All-cause mortality
Persistence/Recurrence of bacteremia
Measure persistence recurrence of bacteremia
Persistence/Recurrence of sepsis
Measure persistence recurrence of sepsis
Organ dysfunction-free days
Measure organ dysfunction free days
Change of Intensive Care Unit (ICU) complications
Reduction of ICU complications
Ventilator-free days (VFDs)
VFD
Length of stay (LOS) at ICU and hospital ward
Measure LOS

Full Information

First Posted
February 5, 2020
Last Updated
December 16, 2021
Sponsor
ExThera Medical Europe BV
Collaborators
ExThera Medical Corporation, Vivantes Clinic Neukölln
search

1. Study Identification

Unique Protocol Identification Number
NCT04260789
Brief Title
Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection
Official Title
Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
August 19, 2020 (Actual)
Primary Completion Date
March 1, 2022 (Anticipated)
Study Completion Date
August 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ExThera Medical Europe BV
Collaborators
ExThera Medical Corporation, Vivantes Clinic Neukölln

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the reduction of pathogen load from the blood in septic patients with suspected, life-threatening bloodstream infection
Detailed Description
With the lack of effective antibiotics for many bloodstream infections, and limited new anti-infectives in development, there is a significant unmet need for new approaches that can help treat drug-resistant infections, especially in patients at high risk. There is an unmet need for a safe and broad-spectrum hemoperfusion therapy that can quickly reduce bacterial load and shorten the duration of bacteremia, preferably without the need to first identifying the type of bacteria present in the blood. There is an emerging need to increase the efficacy of effective antibiotics, e.g., by using hemadsorption as adjunctive therapy, to by quickly reducing bacterial load while scavenging toxins released from bacteria. Finally, there is a medical growing need for an alternative therapy when no effective antibiotic is available. Seraph 100 Microbind Affinity Blood Filter is used to reduce pathogen load during bloodstream infection. Bacteremia or bloodstream infection, also called BSI, occurs when a bacterial infection elsewhere in the body enters the bloodstream. This clinical condition can quickly become life-threatening and progress to sepsis. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection (Singer et al., 2016).When sepsis occurs with extremely low blood pressure, it's called septic shock. Septic shock is fatal in many cases. Sepsis can be triggered by many types of bacteremia although the exact source of the infection often cannot be determined. Some of the most common infections that lead to BSI are lung infections (i.e. pneumonia) and infections in the abdominal area. Patients who are already in the hospital for something else, such as a surgery, are at a higher risk of developing BSI. These infections are even more dangerous when the bacteria are already resistant to antibiotics. The National Institutes of Health (NIH) estimates that over 1 million Americans get sepsis each year. Between 28 and 50 percent of these patients may die from the condition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bloodstream Infection

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Open randomized post-market trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
232 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Other
Arm Description
Treatment with Seraph Filter
Arm Title
Control
Arm Type
No Intervention
Intervention Type
Device
Intervention Name(s)
Seraph 100,The Microbind Affinity Blood Filter
Intervention Description
Treatment with Seraph 100 in one arm
Primary Outcome Measure Information:
Title
Reduction of pathogens load
Description
Reduction of pathogens load from the bloodstream during treatment
Time Frame
4,5 hours +/- 30 min
Secondary Outcome Measure Information:
Title
All-cause mortality
Description
All-cause mortality
Time Frame
90 days
Title
Persistence/Recurrence of bacteremia
Description
Measure persistence recurrence of bacteremia
Time Frame
Day 1, day 2, day 7
Title
Persistence/Recurrence of sepsis
Description
Measure persistence recurrence of sepsis
Time Frame
Daily during ICU stay or at least day 1, day 2, day 7
Title
Organ dysfunction-free days
Description
Measure organ dysfunction free days
Time Frame
Daily during ICU stay or at least day 1, day 2, day 7
Title
Change of Intensive Care Unit (ICU) complications
Description
Reduction of ICU complications
Time Frame
Daily during ICU stay or at least day 1, day 2, day 7
Title
Ventilator-free days (VFDs)
Description
VFD
Time Frame
Daily during ICU stay or at least day 1, day 2, day 7
Title
Length of stay (LOS) at ICU and hospital ward
Description
Measure LOS
Time Frame
During ICU and hospital ward stay or at least day 1, day 2, day 7
Other Pre-specified Outcome Measures:
Title
Treatment emergent adverse events
Description
N (%) of patients with treatment emergent adverse events
Time Frame
Occurrence within the 90 days follow-up period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with sepsis and suspected bloodstream infection Be ≥ 18 years old and ≤ 90 years old Adults receiving IV antibiotic therapy Increase of at least two points of the Sequential Organ Failure Assessment (SOFA) score Subjects that presents Procalcitonin (PCT) levels > 0,5 ng/mL Exclusion Criteria: Subject is currently participating in another clinical investigation Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period Presence of comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results The first dose of the current antibiotic therapy was > 24 h before screening Have Child-Pugh Class C cirrhosis Have platelet count < 30.000/uL Contraindications for heparin sodium for injection Subjects demonstrating any contraindication for this treatment as described in the IFU
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Carla Kikken-Jussen
Phone
+31438200399
Email
carla@extheramedical.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Herwig Gerlach, Prof.
Organizational Affiliation
Vivantes Clinic Neukölln
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Innsbruck
City
Innsbruck
Country
Austria
Individual Site Status
Active, not recruiting
Facility Name
Middelheim Hospital
City
Antwerp
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rogier Nieuwendijk, Dr.
First Name & Middle Initial & Last Name & Degree
Rogier Nieuwendijk, Dr.
Facility Name
Hôpital Erasme
City
Brussels
Country
Belgium
Individual Site Status
Active, not recruiting
Facility Name
CHU Bocage Central
City
Dijon
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hospices Civils de Lyon
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Rimmelé, Prof.
First Name & Middle Initial & Last Name & Degree
Thomas Rimmelé, Prof.
Facility Name
Nouvel Hopital Civil
City
Strasbourg
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Klinikum Aschaffenburg-Alzenau
City
Aschaffenburg
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Vivantes Klinikum Neukölln
City
Berlin
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Städtisches Klinikum Braunschweig GmbH
City
Braunschweig
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan Kielstein, Prof.
First Name & Middle Initial & Last Name & Degree
Jan Kielstein, Prof.
Facility Name
Universität Witten-Herdecke
City
Cologne
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Achim Jörres, Prof.
First Name & Middle Initial & Last Name & Degree
Achim Jörres, Dr.
Facility Name
Universitätsklinikum Essen (AöR)
City
Essen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bartosz Tyczynski, Dr.
First Name & Middle Initial & Last Name & Degree
Bartosz Tyczynski, Dr.
Facility Name
University Hospital Frankfurt
City
Frankfurt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christoph Betz, Dr.
First Name & Middle Initial & Last Name & Degree
Christoph Betz
Facility Name
Universitätsmedizin Greifswald
City
Greifswald
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Asklepios Hospital St. Georg
City
Hamburg
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berthold Bein, Prof.
First Name & Middle Initial & Last Name & Degree
Berthold Bein, Prof.
Facility Name
Medizinische Hochschule Hannover
City
Hannover
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Universität Rostock
City
Rostock
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steffen Mitzner, Prof.
First Name & Middle Initial & Last Name & Degree
Steffen Mitzner, Prof.
Facility Name
Azienda Usl Toscana Centro
City
Florence
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vittorio Pavoni, Dr.
First Name & Middle Initial & Last Name & Degree
Vittorio Pavoni, Dr.
Facility Name
University Hospital, Pisa
City
Pisa
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Forfori, Prof.
First Name & Middle Initial & Last Name & Degree
Francesco Forfori, Prof.
Facility Name
A.Gemelli University Hospital
City
Roma
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Ziekenhuis Gelderse Vallei
City
Ede
Country
Netherlands
Individual Site Status
Active, not recruiting
Facility Name
Medisch Spectrum Twente
City
Enschede
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Albertus Beishuizen, Dr.
First Name & Middle Initial & Last Name & Degree
Albertus Beishuizen, Dr.
Facility Name
Jagiellonia University
City
Kraków
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jaroslaw B. Garlicki, Dr.
First Name & Middle Initial & Last Name & Degree
Jaroslaw B. Garlicki, Dr.
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Clinico San Carlos
City
Madrid
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Royal Surrey NHS Foundation Trust
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lui Forni, Prof.
First Name & Middle Initial & Last Name & Degree
Lui Forni, Prof.

12. IPD Sharing Statement

Learn more about this trial

Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection

We'll reach out to this number within 24 hrs